Gavi, the Vaccine Alliance has initiated a $7.4bn fundraising drive to support the immunisation of 300 million children against 18 diseases, which could save up to eight million lives from 2021-25.

During the same period, governments of developing countries will invest $3.6bn into their vaccine programmes, which is an increase from $1.6bn in 2016-20.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Gavi’s first phase, starting in 2000, supported six vaccines. The support will increase to 18, including inactivated polio vaccine (IPV), rabies and multivalent meningococcal vaccines, by 2025.

The alliance also plans to fund a vaccine stockpile for Ebola after it secures the World Health Organization (WHO) prequalification.

Gavi’s upcoming phase will focus on childhood diseases and expansion of support for human papillomavirus (HPV) vaccine to protect adolescents from cervical cancer.

Furthermore, it will increase stockpiles support for Ebola, cholera, yellow fever and meningitis vaccines.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The alliance aims to provide a total of more than 3.2 billion doses of vaccines to 55 eligible countries over 2021-25.

Gavi, the Vaccine Alliance CEO Dr Seth Berkley said: “Over the past two decades the Vaccine Alliance has helped to protect a generation against some of the world’s deadliest diseases.

“However, 1.5 million people are still dying every year from vaccine-preventable diseases, while climate change, conflict and urbanisation are combining to make it easier for outbreaks to spread. This calls for an urgent response to ensure people continue to be protected against disease, to prevent deadly outbreaks and to help the next generation prosper.”

Since 2000, Gavi has aided in the immunisation of more than 760 million people, saving more than 13 million lives.

Moreover, the alliance will have assisted 18 countries transition out of Gavi support by 2020, enabling them to fund their vaccine programmes.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact